Страна: Ирландия
Език: английски
Източник: HPRA (Health Products Regulatory Authority)
LERCANIDIPINE HYDROCHLORIDE
Teva Pharma B.V.
C08CA13
LERCANIDIPINE HYDROCHLORIDE
10 Milligram
Film Coated Tablet
Product subject to prescription which may be renewed (B)
Dihydropyridine derivatives
Authorised
2013-01-18
1 PACKAGE LEAFLET: INFORMATION FOR THE USER LERCANIDIPINE TEVA PHARMA 10 MG FILM-COATED TABLETS LERCANIDIPINE TEVA PHARMA 20 MG FILM-COATED TABLETS Lercanidipine hydrochloride READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. - If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. IN THIS LEAFLET: 1. What Lercanidipine Teva Pharma is and what it is used for 2. Before you take Lercanidipine Teva Pharma 3. How to take Lercanidipine Teva Pharma 4. Possible side effects 5. How to store Lercanidipine Teva Pharma 6. Further information 1. WHAT LERCANIDIPINE TEVA PHARMA IS AND WHAT IT IS USED FOR Lercanidipine Teva Pharma belongs to a group of medicines called calcium channel blockers (dihydropyridine derivatives). Lercanidipine Teva Pharma is used to treat high blood pressure, also known as hypertension, in adults over the age of 18 years (it is not recommended for children under 18 years old). 2. BEFORE YOU TAKE LERCANIDIPINE TEVA PHARMA DO NOT TAKE LERCANIDIPINE TEVA PHARMA - If you are ALLERGIC (hypersensitive) to lercanidipine or to any OF THE INGREDIENTS in Lercanidipine Teva Pharma - If you have had ALLERGIC REACTIONS to medicines that are closely related to Lercanidipine Teva Pharma (such as amlodipine, nicardipine, felodipine, isradipine, nifedipine or lacidipine) - If you are suffering from CERTAIN HEART DISEASES: - untreated heart failure - obstruction to flow of blood from the heart - unstable angina (angina at rest or progressively increasing) - within one month of a heart attack - If you have SEVERE LIVER OR KIDNEY PROBLEMS - If you are taking medicines that are inhibitors of the CYP3A4 isoenzyme: antifungal medicines (such as ketoconazole or Прочетете целия документ
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Lercanidipine Teva Pharma 10 mg Film-coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One tablet contains 10 mg of lercanidipine hydrochloride, which is equivalent to 9.4 mg of lercanidipine. _Excipients_ One tablet contains 30 mg of lactose monohydrate (equivalent to 28.5 mg of lactose anhydrous) and 0.27 mg of tartrazine aluminium lake (E102). For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film_-_coated tablet. Yellow to dark yellow, round convex film - coated tablet debossed with the number "10" on one side and scored on the other. The tablet can be divided into equal halves. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Lercanidipine is indicated for the treatment of mild to moderate essential hypertension. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _Method of administration_ Oral route The tablet should be swallowed with sufficient liquid (_e.g._ a glass of water). _Dosage_ The recommended dosage is 10 mg orally once a day at least 15 minutes before meals; the dose may be increased to 20 mg depending on the individual patient's response. Dose titration should be gradual, because it may take about 2 weeks before the maximal antihypertensive effect is apparent. Some individuals, not adequately controlled on a single antihypertensive agent, may benefit from the addition of lercanidipine to therapy with a beta - adrenoceptor blocking agent (atenolol), a diuretic (hydrochlorothiazide) or an angiotensin-converting enzyme inhibitor (captopril or enalapril). Since the dose-response curve is steep with a plateau at doses between 20-30 mg, it is unlikely that efficacy will be improved by higher doses; whereas side effects may increase. H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ Прочетете целия документ